Previous close | 392.99 |
Open | 393.00 |
Bid | 0.00 x 0 |
Ask | 0.00 x 0 |
Day's range | 392.80 - 393.00 |
52-week range | 341.00 - 473.65 |
Volume | |
Avg. volume | 746 |
Market cap | 303.509B |
Beta (5Y monthly) | 0.30 |
PE ratio (TTM) | 23.32 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | 9.97 (2.54%) |
Ex-dividend date | 17 Mar 2022 |
1y target est | N/A |
European Commission authorizes a booster dose of AstraZeneca's (AZN) COVID-19 vaccine and approves Merck (MRK) and Roche's (RHHBY) oncology drugs for expanded use.
Roche's (RHHBY) Polivy combination receives the European Commission's approval for patients with previously untreated diffuse large B-cell lymphoma.
As the leader in medical diagnostics, Roche (OTC: RHHB.F) acted quickly to deliver valuable COVID-19 screening tests to the marketplace. Assisted by COVID-related sales, its diagnostics division is now delivering stronger growth than its larger pharmaceuticals division. Roche's medical diagnostics division saw strong growth throughout 2021 and into the begining of 2022.